Want to see IN:JUBLINGREA full AI Analyst Report?
JUBLINGREA Stock Chart & Stats
₹726.00
-₹47.65(-5.70%)
At close: 4:00 PM EST
₹726.00
-₹47.65(-5.70%)
Day’s Range― - ―
52-Week Range₹535.30 - ₹851.85
Previous CloseN/A
Volume517.05K
Average Volume (3M)13.09K
Market Cap
₹108.26B
Enterprise Value₹108.39B
Total Cash (Recent Filing)₹1.90B
Total Debt (Recent Filing)₹7.92B
Price to Earnings (P/E)40.7
Beta1.06
Next Earnings
Jul 21, 2026EPS Estimate
6.7Next Dividend Ex-DateN/A
Dividend Yield0.74%
Share Statistics
EPS (TTM)17.59
Shares Outstanding159,281,140
10 Day Avg. Volume10,350
30 Day Avg. Volume13,091
Financial Highlights & Ratios
PEG Ratio2.89
Price to Book (P/B)2.75
Price to Sales (P/S)1.96
P/FCF Ratio52.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)26.18
Revenue Forecast (FY)₹52.33B
Bulls Say, Bears Say
Bulls Say
Diverse B2B Product MixJubilant Ingrevia's diversified B2B product portfolio across specialty chemicals, nutrition ingredients and chemical intermediates spreads end-market exposure across pharmaceuticals, agrochemicals and food/nutrition. This multi-industry exposure supports steadier demand and reduces single-market cyclicality, underpinning more durable revenue streams and customer relationships over multiple cycles.
Manageable Leverage And Equity GrowthLeverage remaining near ~0.25 with steadily growing equity indicates a conservative capital structure versus prior years. This provides financial flexibility for funding capex, working capital or strategic initiatives without overburdening interest costs, preserving solvency and capacity to invest through downturns or pursue targeted growth moves.
Consistent Operating Cash FlowSustained positive operating cash flow across several years shows the core business generates real cash from operations, enabling internal funding of working capital and some capex. Even with volatile free cash flow, predictable OCF supports operational continuity and reduces dependence on external financing for near-term operational needs.
Bears Say
Weak Cash Conversion / Volatile FCFOperating cash flow materially below net income and a history of negative free cash flow in some years indicate weak cash conversion and erratic FCF generation. This undermines the company's ability to sustainably self-fund growth, dividends or deleveraging and increases sensitivity to capex and working-capital swings over a multi-quarter to multi-year horizon.
Margin Erosion And VolatilityMargins have compressed from prior-cycle highs and show notable volatility, reflecting sensitivity to input costs and pricing power limits. Persistently lower margins reduce reinvestment capacity and return on capital, and volatile profitability makes long-term earnings visibility and planning more difficult for capital allocation and debt servicing.
Declining Capital Efficiency (ROE)A marked decline in return on equity signals weakening capital efficiency and lower effectiveness in converting equity into profits. Over months to years this can pressure investor returns, constrain internal capital availability for expansion, and reflect challenges in pricing, mix or asset utilization that could persist without structural improvements.
Jubilant Ingrevia Ltd. News
JUBLINGREA FAQ
What was Jubilant Ingrevia Ltd.’s price range in the past 12 months?
Jubilant Ingrevia Ltd. lowest stock price was ₹535.30 and its highest was ₹851.85 in the past 12 months.
What is Jubilant Ingrevia Ltd.’s market cap?
Jubilant Ingrevia Ltd.’s market cap is ₹108.26B.
When is Jubilant Ingrevia Ltd.’s upcoming earnings report date?
Jubilant Ingrevia Ltd.’s upcoming earnings report date is Jul 21, 2026 which is in 11 days.
How were Jubilant Ingrevia Ltd.’s earnings last quarter?
Jubilant Ingrevia Ltd. released its earnings results on May 26, 2026. The company reported ₹5.5 earnings per share for the quarter, beating the consensus estimate of ₹4.35 by ₹1.15.
Is Jubilant Ingrevia Ltd. overvalued?
According to Wall Street analysts Jubilant Ingrevia Ltd.’s price is currently Overvalued.
Does Jubilant Ingrevia Ltd. pay dividends?
Jubilant Ingrevia Ltd. pays a Semiannually dividend of ₹2.5 which represents an annual dividend yield of 0.74%. See more information on Jubilant Ingrevia Ltd. dividends here
What is Jubilant Ingrevia Ltd.’s EPS estimate?
Jubilant Ingrevia Ltd.’s EPS estimate is 6.7.
How many shares outstanding does Jubilant Ingrevia Ltd. have?
Jubilant Ingrevia Ltd. has 159,281,140 shares outstanding.
What happened to Jubilant Ingrevia Ltd.’s price movement after its last earnings report?
Jubilant Ingrevia Ltd. reported an EPS of ₹5.5 in its last earnings report, beating expectations of ₹4.35. Following the earnings report the stock price went down -4.492%.
Which hedge fund is a major shareholder of Jubilant Ingrevia Ltd.?
Currently, no hedge funds are holding shares in IN:JUBLINGREA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Jubilant Ingrevia Ltd.
Jubilant Ingrevia Limited, established in 2019 and based in Noida, India, is a global supplier of life science products and comprehensive solutions. The company's operations are divided into three core divisions: Specialty Chemicals, Nutrition & Health Solutions, and Life Science Chemicals. The Specialty Chemicals segment delivers a variety of specialized ingredients, fine chemicals, and crop protection agents, in addition to offering custom development and manufacturing (CDMO) services. Its Nutrition & Health Solutions division focuses on ingredients for both human and animal nutrition and well-being. Meanwhile, the Life Science Chemicals segment provides crucial life science components and a range of specialized ethanol products. Jubilant Ingrevia's extensive portfolio encompasses numerous chemical offerings, including a broad spectrum of pyridine derivatives (such as picolines, cyanopyridines, and various substituted pyridines), essential vitamins like B3 and riboflavin phosphate sodium, and nutritional compounds like premixes and antioxidants. They also produce industrial chemicals like acetic anhydride, ethyl acetate, and various alcohols (absolute alcohol, ethanol), alongside biocompost and gas mixtures. Furthermore, the company supplies a wide array of animal health and nutrition additives, including mineral premixes, stress regulators, amino acids, herbal growth promoters, toxin binders, and enzymes. Beyond its product range, Jubilant Ingrevia offers specialized services in chemical synthesis, covering everything from initial route design and process optimization to scaling up production and commercial manufacturing of intermediates. The company serves a diverse client base across the pharmaceutical, nutrition, agrochemical, consumer goods, and industrial sectors. Originally incorporated as Jubilant LSI Limited, the company adopted its current name, Jubilant Ingrevia Limited, in October 2020.
Technical Analysis
Concord Biotech Ltd.
―
Dishman Carbogen Amcis Ltd.
―
Piramal Pharma Limited
―
Syngene International Ltd.
―
OneSource Specialty Pharma Limited
―






